# Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT05673057** · PHASE1,PHASE2 · RECRUITING · sponsor: **Molecular Partners AG** · enrollment: 249 (estimated)

## Conditions studied

- Leukemia
- Myeloid
- Acute
- Newly Diagnosed

## Interventions

- **DRUG:** MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1
- **DRUG:** MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A
- **DRUG:** MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax
- **DRUG:** MP0533 with Obinutuzumab pretreatment
- **DRUG:** MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML
- **DRUG:** MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients

## Key facts

- **NCT ID:** NCT05673057
- **Lead sponsor:** Molecular Partners AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-29
- **Primary completion:** 2027-12
- **Final completion:** 2029-12
- **Target enrollment:** 249 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673057, "Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05673057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*